Open AccessAssessment of dyslipidemia and atherogenic index of plasma in stage 3 to Stage 5 chronic kidney disease
Author(s) -
Dssk Raju,
G S R Kedari
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns1.5158
Subject(s) - dyslipidemia , kidney disease , medicine , stage (stratigraphy) , creatinine , gastroenterology , endocrinology , cholesterol , very low density lipoprotein , risk factor , renal function , lipoprotein , disease , biology , paleontology
In Chronic Kidney Disease leading factor for morbidity and mortality is Cardiovascular disease. In CKD there is a risk of cardiovascular complications more than 50%. Dyslipidemia is one of leading risk cause for cardiovascular complication in normal healthy individual and also in chronic kidney disease. The Study contains 180 in which 45 as control group and 135 will be CKD individuals with stage 3 to stage 5 each stage consist of 45 each. In all the subjects Serum sample was estimated for blood urea, creatinine, triglycerides, cholesterol, and HDL-C by using fully automatic chemistry analyzer. VLDL, LDL and AIP was calculated. GFR was estimated by MDRD formula. Data was expressed by Mean ±SD. The mean value of triglycerides and VLDL in serum are raised in CKD stages 3 to stage 5 compared with control and it is shown statistically significant (p<0.001). The HDL-C mean value is decreased in CKD stages 3 to stage 5 when compared with control and it is shown statistically significant (p<0.0001). The mean value of serum total cholesterol and LDL-C is not significantly significant in CKD stages 3 to stage 5 compared with control.